Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTO to reissue Lipitor patent

Executive Summary

The U.S. Patent and Trademark Office is reissuing a key Lipitor (atorvastatin) patent covering an enantiomer of the drug. The agency allowed Pfizer to resubmit the patent, which expires in 2011, to correct technical defects after the U.S. Court of Appeals for the Federal Circuit ruled that the patent was invalid due to these defects (1"The Pink Sheet," Aug. 20, 2007, In Brief). Pfizer does not expect generic competition for Lipitor until November 2011 after its settlement with Ranbaxy, the first to file an ANDA and challenge Lipitor patents (2"The Pink Sheet," June 23, 2008, p. 22). Pfizer remains in litigation with Teva and Apotex, which have ANDAs pending for generic Lipitor
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS050571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel